

Table E1. Clinical data of the patients used in the various measurements

	control	CRSwNP	P-value (Fisher's exact test / Mann-Whitney U test*)
Tissue S100A8, S100A9, S100A8/A9 and other inflammatory mediator measurements			
number of subjects	31	40	
Median age (y) (range)	36 (18-70)	49.5 (20-72)	.004*
Gender (male/female)	17/14	24/16	.809
Smokers	9	2	.009
Atopy	15	17	.639
Asthma	6	20	.012
COPD	0	2	.501
AERD	0	3	.251
CT-score (Lund-Mackay), median (range)	0 (0-2)	18 (11-24)	< .0001*
Polyp score (Davos), median (range)	0 (0-0)	4 (2-6)	< .0001*
Serum S100A8/A9 measurements			
number of subjects	33	21	
Median age (range; y)	34 (18-70)	46 (29-64)	.005*
Gender (male/female)	17/16	14/7	.398
Smokers	10	2	.099
Atopy	14	10	.783
Asthma	5	10	.014
COPD	0	2	.147
AERD	0	2	.147
CT-score (Lund-Mackay), median (range)	0 (0-2)	17 (11-24)	< .0001*
Polyp score (Davos), median (range)	0 (0-0)	4 (2-6)	< .0001*

Nasal secretions S100A8/A9 measurements

number of subjects	15	15	
Median age (range; y)	29 (18-57)	42 (29-64)	.019*
Gender (male/female)	7/8	10/5	.462
Smokers	5	1	.169
Atopy	3	7	.245
Asthma	3	5	.682
COPD	0	0	1
AERD	0	1	1
CT-score (Lund-Mackay), median (range)	0 (0-2)	17 (11-24)	< .0001*
Polyp score (Davos), median (range)	0 (0-0)	4 (2-6)	< .0001*

CRSwNP: chronic rhinosinusitis with nasal polyps; COPD: Chronic Obstructive Pulmonary Disease; AERD: aspirin exacerbated respiratory disease